Previous 10 | Next 10 |
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Austra...
Gainers: Five Prime Therapeutics (FPRX) +259%.Fuel Tech (FTEK) +96%.Equillium (EQ) +61%.Immuron (IMRN) +29%.Genfit (GNFT) +27%.Performance Shipping (PSHG) +25%.Revlon (REV) +21%.Eastside Distilling (EAST) +20%.Vaxart (VXRT) +20%.Myomo (MYO) +19%.Losers: eGain (EGAN) -29%.S...
Immuron (IMRN) gains 26% premarket in reaction to the announcement that the Naval Medical Research Center ((NMRC)) has completed the characterization of the colostrum harvested from cows immunized with the experimental vaccine developed to target Campylobacter and Enterotoxigenic E....
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETEC Immuron executes a Research Agreement with PCI Clinical S ervices to manufacture drug product Two human phase II clinical trials to be co...
Gainers: Organovo Holdings (ONVO) +12%, Lantern Pharma (LTRN) +11%, Cancer Genetics (CGIX) +10%, American Well (AMWL) +10%, Immuron (IMRN) +9%.Losers: Avenue Therapeutics ATXI -57%, Zynex ZYXI -27%, Fortress Biotech FBIO -22%, &...
Immuron (IMRN) to recommence CMC related activities regarding its investigational drug IMM-124E, required for study of Travelers' Diarrhea or TDUniformed Services University recommended planned clinical trial program to evaluate the efficacy of non-antibiotic OTC products in TD and will provi...
Lizhi (LIZI) +46%. as Government picks Lizhi its backed pilot program to bolster local online audiovisual industry.Acorn (ATV) +31% on revised going private transaction for $21/share.LMP Automotive (LMPX) +21%. to acquire 70% interest in New York’s largest franchise...
Key Points Immuron’s IMM-124E IND Program recommences Uniformed Services University to recommence planned Travelers’ Diarrhea clinical study COVID-19 - Consultancy Agreement with Infectious Disease Epidemiologist at Wayne S...
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathoge...
Liquid Media (NASDAQ: YVR ) +63% . More news on: Liquid Media Group Ltd., Milestone Pharmaceuticals Inc., CymaBay Therapeutics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Sales Highlights: MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Travelan ® , an over-the-counter immune ...
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug A...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed a...